依达拉奉治疗急性脑梗死46例临床疗效观察

Observation of Clinical Efficacy of Edaravone for the Treatment of 46 Cases of Acute Cerebral Infarction

【目的】探讨依达拉奉治疗急性脑梗死的临床疗效。【方法】选择本院2007年7月至2009年7月收治的急性脑梗死患者90例，随机分为两组，观察组46例和对照组44倒，对照组采用常规内科治疗，观察组在对照组治疗基础上给予依达扛奉活疗。对两组患者治疗前后进行神经功能缺损评分，治疗后效果进行评定。【结果】两组总有效率比较，差异有显著性（P〈O．01）；治疗后两组NIHSS评分比治疗前明显下降，但治疗组较对照组改善更明显（P〈O．01）；治疗后10d两组CSS评分均有所减低．但治疗组CSS评分减低明显优于对照组（P〈0．01）。【结论】依达扛奉治疗急性脑梗死临床效果显著，能够显著改善急性脑梗死患者神经功能，值得临床借鉴。

[Objective] To explore the clinical efficacy of edaravone for the treatment of acute cerebral infarction. [Methods]Totally 90 cases of acute cerebral infarction were selected from July 2007 to July 2009 and randomly divid- ed into observation group（ n = 46） and control group（ n = 44）. The control group received the routine medical treat- ment. The observation group was given edaravone on the basis of the therapy of the control group. Neurologic impairment score was evaluated before and after treatment. The clinical efficacy was evaluated after treatment. [Results] There was significant difference in the total effective rate between two groups （ P〈0.01）. Compared with before treatment, NIHSS score in two groups decreased after treatment, but the observation group improved more signifi- cantly than the control group（ P 〈0.01）. At 10 days after treatment, the CSS scores in two groups decreased, but the observation group improved more significantly than the control group（ P 〈0. 01）. [Conclusion] Edaravone for the treatment of acute cerebral infarction has significant clinical efficacy, and can improve the neurologic function of acute cerebral infarction. Therefore, it is worth to be extended in clinical application.